Please login to the form below

Not currently logged in
Email:
Password:

UCB appoints GSK's Mark Bodmer as head of immunology

Also promotes Michele Antonelli to managing director of UCB France

UCB has appointed Mark Bodmer as head of immunology in its New Medicines research and early development division.

The company has also promoted Michele Antonelli to managing director of UCB France. He previously worked as head of the company's technical operations and quality team, a position that will now be filled by UCB's chief operating officer Mark McDade.

Mark Bodmer - UCB, head of immunologyMichele Antonelli - UCB, MD France
Mark Bodmer and Michele Antonelli

Bodmer joins the Belgium-based pharma company from GlaxoSmithKline (GSK), where he most recently served as senior VP of Immuno-Inflammation, Medicines, Discovery and Development.

In his new role Bodmer will be based at UCB's Slough, UK research site. He will sit on the New Medicines leadership team and report to the division's president Ismail Kola.

In a statement, UCB said: “To date Mark's career has spanned research leadership, corporate leadership and business development and we are looking forward to the wealth of experience he will bring to UCB.”

Bodmer is the third new member of the New Medicines leadership team to have recently joined UCB, following the appointments of Duncan McHale as head of global exploratory development and Peter Theil as head of non-clinical development.

UCB's New Medicines is based around two European research hubs - Braine-l'Alleud in Belgium for central nervous system (CNS) diseases and Slough for immunological disorders – whose work covers discovery research through to clinical proof of concept.

Earlier this year UCB New Medicines signed a $6m collaboration with Harvard University in the US. The first project to be funded was a study looking at developing antibodies with potential in diabetes and metabolic disorders.

5th January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics